Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Janux Therapeutics (JANX) Leases (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Leases for 5 consecutive years, with $18.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 4.58% to $18.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.4 million, a 4.58% decrease, with the full-year FY2025 number at $18.4 million, down 4.58% from a year prior.
  • Leases was $18.4 million for Q4 2025 at Janux Therapeutics, down from $18.9 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $22.8 million in Q2 2022 to a low of $130000.0 in Q1 2022.
  • A 5-year average of $17.1 million and a median of $19.9 million in 2024 define the central range for Leases.
  • Peak YoY movement for Leases: skyrocketed 16766.92% in 2023, then fell 8.04% in 2025.
  • Janux Therapeutics' Leases stood at $185000.0 in 2021, then skyrocketed by 11942.7% to $22.3 million in 2022, then fell by 6.47% to $20.8 million in 2023, then dropped by 7.45% to $19.3 million in 2024, then dropped by 4.58% to $18.4 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Leases are $18.4 million (Q4 2025), $18.9 million (Q3 2025), and $18.5 million (Q2 2025).